Details of the Drug

General Information of Drug (ID: DM71Q69)

Drug Name
ABBV-184
Indication
Disease Entry ICD 11 Status REF
Acute myeloid leukaemia 2A60 Phase 1 [1]
Non-small-cell lung cancer 2C25.Y Phase 1 [1]
Drug Type
TCR-T cell therapy
Cross-matching ID
TTD ID
D7QHV6
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
T-cell surface glycoprotein CD3 (CD3) TTUN7MC NOUNIPROTAC Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT04272203) A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated Cancers. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of AbbVie.